# Jiangsu Bochuang Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiangsu-bochuang-biotechnology

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.bioboch.com
- Latest round: Series A (Mar 6, 2026)
- Investors on record: 2

## About

Established in 2022 and based in Suzhou, China, Jiangsu Bochuang Biotechnology Co,. LTD., trading as Jiangsu Bochuang Biotechnology, operates as a medical prosthetic product developer that focuses on the production and sales of collagen repair products and membrane repair products. The company was recognized as the National High-tech Enterprise. It cooperated with East China University of Science and Technology and Shanghai University. Changsheng Liu, the company's chief consultant, is an academician of the Chinese Academy of Sciences. In July 2023, it announced the successful trial production of its self-developed Type I newborn highly active collagen raw materials. In March 2026, Jiangsu Bochuang Biotechnology raised a series A funding from Sunland Capital.

The company provides collagen repair products and membrane repair products. Its products mainly include the artificial cornea, periosteum, dura mater, and nerve sheath tubes, such as E-Gide and E-Col. The artificial cornea is prepared using EDP technology, and the product's transmittance can reach over 95%. The company also develops an EDP technology platform for electrochemical deposition of biomolecules.

The company will use the funds for the subsequent development and commercial conversion of the core products, Oral Bone Tissue Guiding Membrane (E-Gide) and Highly Transparent Collagen Prosthetic Cornea (E-Colcornea), as well as for the development of prosthetic heart valve.

This investment aims to support Jiangsu Bochuang Biotechnology's research and innovation in the field of medical membrane materials and accelerate the market promotion of innovative products such as high-end artificial corneas, periosteums, and dura maters.

## Funding rounds

- Series A, Mar 6, 2026 — Sunland Capital
- Angel, Mar 9, 2023 — Dalton Venture

## Investors

- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Angel
- Sunland Capital — Series A